BCR and B-cell chronic lymphocytic leukemia: Similarly, although active in the clinic, ibrutinib51 and idelalisib54 do not induce significant apoptosis in vitro at clinically relevant concentrations, suggesting that BCR antagonists may not kill the CLL cells directly.